KRAS and non-small cell lung carcinoma: Our study shows that KRAS G12/G13 mutations in cfDNA assessed using ddPCR are significantly associated with poor clinical outcomes, in terms of disease control, PFS and OS among patients with NSCLC treated with first-line systemic treatment, delineating the prognostic value of plasma KRAS mutations in NSCLC.